Home Slider

Welcome to Aurobindo Pharma USA: Committed to healthier life.

Product News

Aurobindo Receives FDA Approval for Azelastine Hydrochloride Nasal Spray 0.15% (205.5 mcg per spray)

East Windsor, N.J. – Aurobindo Pharma Limited has received final approval from U.S. Food and Drug Administration for its Abbreviated New Drug Application Azelastine Hydrochloride Nasal Spray 0.15% (205.5 mcg per spray). Aurobindo Pharma’s Azelastine Hydrochloride Nasal Spray 0.15% (205.5 mcg per spray) are an AB-rated generic equivalent to the reference listed drug (RLD), Astepro® Nasal Spray, 0.15%, of Mylan Specialty,

[...] Read more

Industry News

Aurobindo Pharma’s subsidiary Acrotech Biopharma to acquire portfolio of seven marketed oncology injectable products from Spectrum Pharmaceuticals

Acquisition for an upfront purchase price of $160 million in cash plus up to $140 million on achieving regulatory and sales-based milestones Acquired portfolio includes seven branded oncology injectable products which are currently being marketed. The acquisition also brings-in an experienced branded commercial infrastructure in the US The portfolio is expected to generate a revenue

[...] Read more

Social Responsibility

Dispensary of Hope

Aurobindo became a partner to Dispensary of Hope in 2012. In only 5 short years, Aurobindo has donated 3,736,413 doses of medicine. Almost 30% of these doses were donated in 2017. This is largely due to the quick and additional response to Hurricane Harvey relief efforts with additional donations. Pharmaceutical products are provided to the

[...] Read more